BChE-IN-4 is a highly potent inhibitor of the enzyme butyrylcholinesterase, capable of crossing the blood-brain barrier. It effectively reduces learning and memory impairments resulting from a deficiency in cholinergic activity in a mouse model. BChE-IN-4 holds promise for further investigation in the field of Alzheimer's disease research [1].

BChE-IN-4 (compound 1) administered at doses of 10, 20, and 30 mg/kg effectively mitigates learning and memory impairments associated with cholinergic deficits in an Alzheimer's disease (AD) mouse model, without inducing adverse motor effects at 30 mg/kg. Studies on adult male Albino Swiss CD-1 mice with scopolamine-induced memory impairments revealed that BChE-IN-4 significantly enhances step-through latencies, indicating memory improvement. Additionally, in C57BL/6J mice (18-22 g), a 30 mg/kg dosage enhanced long-term memory retrieval by day 12 in the Barnes maze task, though it did not initially improve learning abilities or short-term memory retrieval by day 5. Further examination at a 30 mg/kg dosage, suspended in 1% Tween 80, confirmed that BChE-IN-4 does not affect locomotor activity nor cause motor deficits in rotarod tests, affirming its safety and efficacy in improving cognitive functions without impairing motor skills.